Breaking News Instant updates and real-time market news.

2018-04-12 08:33:38 ARNA Arena Pharmaceuticals $36.20 0.13 (0.36%) 08:33 04/12/18 04/12 08:33 04/12/18 08:33	Arena Pharmaceuticals to present Phase 2 ralinepag results at ISHLT Arena Pharmaceuticals announced that data from a post-hoc analysis of the 22-week Phase 2 clinical study for its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension, will be presented at the International Society for Heart and Lung Transplantation 2018 Annual Meeting on April 14. The meeting is taking place April 11-14 in Nice, France. "Patients receiving ralinepag experienced improvements in their mortality risk category using three risk scoring methodologies developed and utilized globally," said Dr. Raymond Benza. "These positive data further highlight the potential of ralinepag as an effective treatment of PAH, and I look forward to determining the impact of ralinepag on clinical outcomes in the Phase 3 clinical program." Arena previously announced topline Phase 2 results for ralinepag in PAH in which the primary efficacy analysis demonstrated a statistically significant absolute change from baseline in pulmonary vascular resistance compared to placebo. Ralinepag also demonstrated numerical improvement in 6-minute walk distance relative to placebo. Adverse events observed in the study were consistent with other prostacyclin treatments for the management of PAH.	13 Apr 20 Apr
ARNA Arena Pharmaceuticals $36.20 0.13 (0.36%) 03/21/18 SBSH 03/21/18 NO CHANGE Target $62 SBSH Buy Arena Pharmaceuticals price target raised to $62 from $55 at Citi Citi analyst Joel Beatty raised his price target for Arena Pharmaceuticals to $62 after the company announced positive Phase 2 topline results for etrasimod in ulcerative colitis. The analyst increased his market penetration projections for etrasimod and maintained a 60% probability of success for the drug. He keeps a Buy rating on Arena Pharmaceuticals. 03/20/18 03/20/18 UPGRADE On The Fly: Top five analyst upgrades Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Universal Display (OLED) upgraded to Buy from Hold at Gabelli with analyst Hendi Susanto saying he views the negative market response to a Bloomberg report that Apple (AAPL) is designing and producing MicroLED display prototypes as an overreaction and a buying opportunity. 2. Oneok (OKE) upgraded to Buy from Hold at Jefferies with analyst Christopher Sighinolfi saying he is confident in Oneok's ability to hit target returns on $4.2B of its current projects following a recent meeting with management. 3. PPG (PPG) upgraded to Buy from Hold at Deutsche Bank with analyst David Begleiter saying he believes the company's capital deployment and "valuation discount" are attractive. 4. Roku (ROKU) upgraded to Perform from Underperform at Oppenheimer with analyst Jason Helfstein upgraded Roku (ROKU) to Perform citing valuation and the company's opportunity in virtual multichannel video programming distribution. 5. Arena Pharmaceuticals (ARNA) upgraded to Buy from Hold at Needham with analyst Alan Carr citing the company's "impressive results" from its Phase 2 Ulcerative Colitis study, noting that the the safety and tolerability data components are also "encouraging." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here. 03/20/18 JMPS 03/20/18 NO CHANGE Target $79 JMPS Outperform Arena Pharmaceuticals price target raised to $79 from $63 at JMP Securities JMP Securities analyst Jason Butler said Arena Pharmaceuticals' top-line results for etrasimod in ulcerative colitis meet or beat his best-case expectations and he has increased his view of the probability of success for etrasimod in UC to 75% from 50% following the report of the data. Given the higher odds he places on the success of the drug in that indication, Butler raised his price target on Arena shares to $79 from $63 and keeps an Outperform rating on the stock. 03/20/18 NEED 03/20/18 UPGRADE Target $60 NEED Buy Arena Pharmaceuticals upgraded to Buy at Needham on phase 2 UC data As reported earlier, Needham analyst Alan Carr upgraded Arena Pharmaceuticals to Buy from Hold with a price target of $60. Carr cites the company's "impressive results" from its Phase 2 Ulcerative Colitis study unveiled yesterday, noting that the the safety and tolerability data components are also "encouraging". The analyst adds that the favorable outcome warrants an update to his pricing model, particularly in light of "substantial" unmet need in the Inflammation space where there are few S1P modulators currently in development.

2018-04-12 08:33:38

ARNA

Arena Pharmaceuticals

$36.20: 0.13 (0.36%)

08:33

04/12/18

04/12

08:33

04/12/18

08:33

Arena Pharmaceuticals to present Phase 2 ralinepag results at ISHLT

Arena Pharmaceuticals announced that data from a post-hoc analysis of the 22-week Phase 2 clinical study for its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension, will be presented at the International Society for Heart and Lung Transplantation 2018 Annual Meeting on April 14. The meeting is taking place April 11-14 in Nice, France. "Patients receiving ralinepag experienced improvements in their mortality risk category using three risk scoring methodologies developed and utilized globally," said Dr. Raymond Benza. "These positive data further highlight the potential of ralinepag as an effective treatment of PAH, and I look forward to determining the impact of ralinepag on clinical outcomes in the Phase 3 clinical program." Arena previously announced topline Phase 2 results for ralinepag in PAH in which the primary efficacy analysis demonstrated a statistically significant absolute change from baseline in pulmonary vascular resistance compared to placebo. Ralinepag also demonstrated numerical improvement in 6-minute walk distance relative to placebo. Adverse events observed in the study were consistent with other prostacyclin treatments for the management of PAH.

13
Apr
20
Apr

ARNA Arena Pharmaceuticals

$36.20: 0.13 (0.36%)

03/21/18: SBSH

03/20/18

03/20/18: JMPS

03/20/18: NEED

TODAY'S FREE FLY STORIES

04:55 04/21/18 04/21 04:55 04/21/18 04:55 Conference/Events	International Monetary Fund & World Bank Group to co-host an annual meeting » 2018 Spring Meeting will… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial
SPX S&P 500 , SPY SPDR S&P 500 ETF Trust $266.66 -2.18 (-0.81%) 18:08 04/20/18 04/20 18:08 04/20/18 18:08 Periodicals	North Korea to suspend nuclear and ICBM tests, Bloomberg reports » North Korea also plans to… North Korea also plans to dismantle its nuclear testing site, according to Bloomberg SPX S&P 500 SPY SPDR S&P 500 ETF Trust $266.66 -2.18 (-0.81%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
ADM Archer Daniels $45.50 -0.295 (-0.64%) , BG Bunge $73.72 -1.935 (-2.56%) 18:03 04/20/18 04/20 18:03 04/20/18 18:03 Periodicals	Archer Daniels, Bunge talks end without merger deal, Bloomberg reports » Advanced merger… Advanced merger discussions between Bunge (BG) and Archer Daniels Midland (ADM) have ended without a deal, Bloomberg reports, citing people familiar with the matter. ADM was not able to circumvent potential antitrust issues, the report says. A combination of the two companies would've created a company that, at least in terms of revenue, approaches the size of Cargill, the report notes. ADM Archer Daniels $45.50 -0.295 (-0.64%) BG Bunge $73.72 -1.935 (-2.56%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	02 May 30 May
CE Celanese $111.69 0.56 (0.50%) 18:02 04/20/18 04/20 18:02 04/20/18 18:02 Hot Stocks	Celanese announces price increases in Asia » Celanese will increase… Celanese will increase list and off-list selling prices for acetyl intermediate products, raising Acetic Acid price by $100 per ton and Acetic Anhydride by $125 per ton. The price increases below will be effective immediately or as contracts otherwise allow, and are incremental to any previously announced increases. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	01 May 30 May
IOTS Adesto Technologies $8.65 -0.2 (-2.26%) 17:33 04/20/18 04/20 17:33 04/20/18 17:33 Hot Stocks	Breaking Hot Stocks news story on Adesto Technologies » 180 Degree Capital lowers… 180 Degree Capital lowers stake in Adesto Technologies to 5.8% from 7.3% 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	23 May

SIGM Sigma Designs $6.30 0.1 (1.61%) 17:22 04/20/18 04/20 17:22 04/20/18 17:22 Hot Stocks	Sigma Designs to delay filing Annual Report on Form 10-K » Sigma Designs is unable… Sigma Designs is unable to file its annual report on Form 10-K for the fiscal year ended February 3, 2018 within the prescribed period due to the recently completed sale of its assets related to the Company's Z-Wave business, which transaction was completed on April 18, 2018. The process of compiling and reporting the information required to be included in the Form 10-K, as well as the completion of the required review of its financial information, could not be completed by the filing deadline without incurring undue hardship and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, the registrant will file the Annual Report no later than the fifteenth calendar day following the prescribed due date. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
BRK.A Berkshire Hathaway $300,140.00 -260 (-0.09%) , BRK.B Berkshire Hathaway $200.09 -0.32 (-0.16%) … 17:22 04/20/18 04/20 17:22 04/20/18 17:22 Hot Stocks	Breaking Hot Stocks news story on Berkshire Hathaway, Berkshire Hathaway, Torchmark » Berkshire Hathaway… Berkshire Hathaway reports 5.6% passive stake in Torchmark BRK.A Berkshire Hathaway $300,140.00 -260 (-0.09%) BRK.B Berkshire Hathaway $200.09 -0.32 (-0.16%) TMK Torchmark $87.22 0.02 (0.02%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
SMHI SEACOR Marine Holdings $22.90 -0.86 (-3.62%) , CG Carlyle Group $20.85 0.15 (0.72%) 17:17 04/20/18 04/20 17:17 04/20/18 17:17 Syndicate	SEACOR Marine Holdings announces $56.9M private placement of common stock » SEACOR Marine Holdings… SEACOR Marine Holdings (SMHI) announced that it has entered into a subscription agreement with qualified institutional buyers and other accredited investors for the private placement of approximately 2,842,750 shares of its common stock at a purchase price of $20.00 per share. The gross proceeds to SEACOR Marine will be $56,855,000. SEACOR Marine intends to use the net proceeds of the Private Placement for general corporate purposes. Concurrent with the Private Placement, SEACOR Marine and the Carlyle Group (CG) have agreed to exchange $50M of SEACOR Marine's outstanding 3.75% convertible senior notes due December 2022 for a total of approximately 1.9M shares of common stock at an implied exchange price of $26.50 per share. SEACOR Marine and the Carlyle Group also agreed to amend the notes that will remain outstanding to (i) increase the coupon from 3.75% per annum to 4.25% per annum and (ii) extend the maturity of the Notes by 12 months to December 2023. SMHI SEACOR Marine Holdings $22.90 -0.86 (-3.62%) CG Carlyle Group $20.85 0.15 (0.72%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	12 Jun
AVAV AeroVironment $56.66 -0.15 (-0.26%) 17:12 04/20/18 04/20 17:12 04/20/18 17:12 Hot Stocks	AeroVironment awarded $44.7M U.S. Army contract modification » AeroVironment was awarded… AeroVironment was awarded a $44,691,196 modification to contract W31P4Q-17-C-0193 for hardware and parts for Block 10C inert training vehicles, Block 10C all up rounds, multi pack launchers, and modular battery payloads. Work will be performed in Simi Valley, California, with an estimated completion date of Sept. 19, 2019. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 May
XLE Energy Select Sector SPDR $73.30 -0.36 (-0.49%) , XLU Utilities SPDR $50.29 -0.45 (-0.89%) … 17:10 04/20/18 04/20 17:10 04/20/18 17:10 General news	Week ending ETF Scorecard: Energy outperforms again, Staples lag » S&P500 SECTORS:… S&P500 SECTORS: Energy (XLE) up 2.7%... Industrials (XLI) up 2.2%... Consumer Discretionary (XLY) up 1.7%... Financials (XLF) up 1.5%... Materials (XLB) up 1.5%... Utilities (XLU) up 1.0%...Telecom (IYZ) up 1.0%...Health Care (XLV) up 0.3%... Technology (XLK) down 0.2%... Real Estate (IYR) down 0.7%... Consumer Staples (XLP) down 4.0%. COMMODITY: Gold (GLD) down 0.7%... Silver (SLV) up 2.9%... Copper (JJC) up 0.3%... Crude Oil (USO) up 1.5%... Natural Gas (UNG) flat... Grains (JJG) up 2.0%. FIXED INCOME: High Yield (HYG) down 0.5%... Investment Grade (LQD) down 1.3%... Long-term Treasury (TLT) down 2.0%... Mid-term Treasury (IEF) down 1.0%... Short-term Treasury (SHY) down 0.1%. STRATEGY: Value (IWD) up 0.6%... Growth (IWF) up 0.6%. XLE Energy Select Sector SPDR $73.30 -0.36 (-0.49%) XLU Utilities SPDR $50.29 -0.45 (-0.89%) IYR DJ US Real Estate Index Fund $73.94 -0.62 (-0.83%) XLP Consumer Staples Sector SPDR $50.49 -0.85 (-1.66%) XLY Consumer Discretionary Sector SPDR $102.97 -1.06 (-1.02%) XLB S&P Select Materials SPDR $59.00 -0.36 (-0.61%) XLF Financial Select Sector $27.89 0.015 (0.05%) XLV Health Care Select Sector SPDR $82.10 -0.45 (-0.55%) XLK Technology Select Sector SPDR $66.18 -0.97 (-1.44%) XLI Industrial Select Sector SPDR $75.59 -0.32 (-0.42%) GLD SPDR Gold Trust $126.61 -1.01 (-0.79%) SLV iShares Silver Trust $16.14 -0.11 (-0.68%) USO United States Oil Fund $13.76 -0.01 (-0.07%) UNG United States Natural Gas Fund $22.56 0.475 (2.15%) HYG iShares iBoxx $ High Yield Corporate Bond $85.91 -0.19 (-0.22%) LQD iShares iBoxx $ Investment Grade Corporate Bond $115.47 -0.49 (-0.42%) TLT iShares 20+ Year Treasury Bond Fund $118.47 -0.88 (-0.74%) IEF iShares 7-10 Year Treasury Bond ETF $101.57 -0.355 (-0.35%) SHY iShares 1-3 Year Treasury Bond $83.26 -0.03 (-0.04%) IWD iShares Russell 1000 Value $121.38 -0.61 (-0.50%) IWF iShares Russell 1000 Growth $137.65 -1.53 (-1.10%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

JAGX Jaguar Health $0.16 -0.0051 (-3.02%) 17:07 04/20/18 04/20 17:07 04/20/18 17:07 Syndicate	Breaking Syndicate news story on Jaguar Health » Jaguar Health files to… Jaguar Health files to sell 29.41M shares of common stock for holders 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
WMT Walmart $86.98 -0.9 (-1.02%) , FB Facebook $166.29 -1.82 (-1.08%) 17:05 04/20/18 04/20 17:05 04/20/18 17:05 Hot Stocks	Walmart says Kevin Systrom will not stand for re-election to board » Walmart and Systrom, the… Walmart and Systrom, the co-founder and CEO of Instagram, mutually agreed he would not stand for re-election as he prioritizes work, board responsibilities and other outside commitments. Systrom joined the Board in 2014 and served as chair of the Technology and eCommerce Committee and was a member of the Compensation and Management Development Committee. WMT Walmart $86.98 -0.9 (-1.02%) FB Facebook $166.29 -1.82 (-1.08%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	20 Apr 25 Apr 17 May 30 May 01 Jun
WMT Walmart $86.98 -0.9 (-1.02%) , MCD McDonald's $158.77 -0.76 (-0.48%) 17:03 04/20/18 04/20 17:03 04/20/18 17:03 Hot Stocks	Walmart announces McDonald's Steve Easterbrook as independent nominee to board » "This year's… "This year's Proxy materials seek shareholders' votes on 11 director nominees, two company proposals and two shareholder proposals. Dr. James Cash is retiring from the Board, and Kevin Systrom will not stand for re-election. As Walmart maintains its commitment to an independent Board, it announced Steve Easterbrook, CEO of McDonald's, as a new independent nominee." WMT Walmart $86.98 -0.9 (-1.02%) MCD McDonald's $158.77 -0.76 (-0.48%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	20 Apr 30 Apr 17 May 24 May 30 May 30 May 01 Jun
SPY SPDR S&P 500 ETF Trust $266.66 -2.18 (-0.81%) , USO United States Oil Fund $13.76 -0.01 (-0.07%) … 17:00 04/20/18 04/20 17:00 04/20/18 17:00 General news	Weekly CFTC Commitment of Traders highlights » S&P500 net long 2.5K… S&P500 net long 2.5K contracts, 11-week high in net longs... 10-YEAR U.S. TREASURY net short 371.7K contracts, up 41K from prior week... U.S. DOLLAR INDEX net short 2.4K contracts, 9-week high in net shorts... EURO net long 151.5K contracts, multi-year high in net longs... BRITISH POUND net long 47.7K contracts, 4th straight week of multi-year high net longs... JAPANESE YEN net long 2.6K contracts, down 0.2K from prior week... CANADIAN DOLLAR net short 30.3K contracts, down 1.3K from prior week... CRUDE OIL net long 728.1K contracts, 10-week high in net longs... GOLD net long 163.1K contracts, up 7.6K from prior week... COPPER net long 30.7K contracts, 4-week high in net longs. SPY SPDR S&P 500 ETF Trust $266.66 -2.18 (-0.81%) USO United States Oil Fund $13.76 -0.01 (-0.07%) GLD SPDR Gold Trust $126.61 -1.01 (-0.79%) FXE Euro Currency Trust $118.04 -0.65 (-0.55%) FXC CurrencyShares Canadian Dollar Trust $77.37 -0.54 (-0.69%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
CTXR Citius Pharmaceuticals $2.86 0.01 (0.35%) 16:59 04/20/18 04/20 16:59 04/20/18 16:59 Syndicate	Breaking Syndicate news story on Citius Pharmaceuticals » Citius Pharmaceuticals… Citius Pharmaceuticals files to sell 1.45M shares of common stock for holders 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

16:55 04/20/18 04/20 16:55 04/20/18 16:55 General news	Treasury Closing Summary: » Treasury Closing Summary:… Treasury Closing Summary: bonds and stocks again closed lower amid a variety of issues, though some of the blame for the weakness in stocks has been the run up in yields with the 10-year approaching 3%. Indeed, Treasury yields extended higher Friday, continuing the trend that had been in effect most of the week. The long end again was the underperformer, resulting in a steeper yield curve to 49.9 bps, from 44.8 bps at the beginning of the week (which was the narrowest since 2007). There's been a lot of talk this week of the implications of an inverted yield curve and its correlation with recessions. That weighed on equity sentiment. Just the opposite was evident in Europe where bourses were mostly higher, while EBG yields dipped on the day, led by a better than 4 bps drop in the Gilt to 1.477% after BoE's Carney comments.
FPI Farmland Partners $7.85 -0.24 (-2.97%) 16:51 04/20/18 04/20 16:51 04/20/18 16:51 Syndicate	Breaking Syndicate news story on Farmland Partners » Farmland Partners files… Farmland Partners files $300M mixed securities shelf 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
GIFI Gulf Island Fabrication $8.85 0.05 (0.57%) 16:51 04/20/18 04/20 16:51 04/20/18 16:51 Hot Stocks	Breaking Hot Stocks news story on Gulf Island Fabrication » PVAM Perlus Microcap Fund… PVAM Perlus Microcap Fund reports 5.3% passive stake in Gulf Island Fabrication 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	25 Apr 27 Apr
AMID American Midstream Partners $11.45 -0.1 (-0.87%) 16:46 04/20/18 04/20 16:46 04/20/18 16:46 Syndicate	American Midstream Partners files $150M preferred unit offering » The offering is for $150M… The offering is for $150M of Series F fixed-to-floating cumulative redeemable perpetual preferred units representing limited partner interests. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
AMID American Midstream Partners $11.45 -0.1 (-0.87%) 16:41 04/20/18 04/20 16:41 04/20/18 16:41 Syndicate	American Midstream Partners requests withdrawal of registration statement » The Partnership has… The Partnership has elected not to pursue the sale of securities pursuant to the registration statement, file No. 333-222810, and no securities have been offered or sold pursuant to it. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

SSC Seven Stars Cloud Group $2.67 -0.1 (-3.61%) 16:40 04/20/18 04/20 16:40 04/20/18 16:40 Syndicate	Breaking Syndicate news story on Seven Stars Cloud Group » Seven Stars Cloud Group… Seven Stars Cloud Group files to sell 34.73M shares of common stock for holders 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
HNI HNI Corporation $35.35 -0.28 (-0.79%) 16:39 04/20/18 04/20 16:39 04/20/18 16:39 Hot Stocks	HNI Corporation CEO says 'seeing increased inflationary pressures' » "We continue to… "We continue to project solid top line growth and strong productivity improvement in 2018. We are seeing increased inflationary pressures. While we are working to offset these cost increases, they will have a negative impact on our results, particularly in the second quarter. We continue to be excited about our competitive position and expect to deliver solid profit improvement for the year," said CEO Askren. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	01 May 24 May 25 May
HNI HNI Corporation $35.35 -0.28 (-0.79%) 16:38 04/20/18 04/20 16:38 04/20/18 16:38 Earnings	HNI Corporation narrows FY18 adjusted EPS view to $2.40-$2.70 from $2.40-$2.80 » FY18 consensus $2.54. The… FY18 consensus $2.54. The Corporation continues to expect full year organic sales to be up 5%-8%. Including the impact of closing and divesting small office furniture companies, full year sales are expected to be up 1%-4%. FY18 consensus $2.24B. The Corporation estimates full year non-GAAP earnings per share to be in the range of $2.40-$2.70, which excludes restructuring and transition costs. This compares to prior guidance of non-GAAP earnings per share of $2.40-$2.80. The impact of rising input costs is primarily driving the reduced earnings outlook. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	01 May 24 May 25 May
HNI HNI Corporation $35.35 -0.28 (-0.79%) 16:35 04/20/18 04/20 16:35 04/20/18 16:35 Earnings	HNI Corporation sees Q2 adjusted EPS 28c-38c ex-costs, consensus 56c » Sees Q2 organic revenue… Sees Q2 organic revenue growth of 4%-7%, consensus $532.9M. Including the impact of closing and divesting small office furniture companies, second quarter sales are expected to be up 1%-4%. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	01 May 24 May 25 May
WHR Whirlpool $149.43 -2.505 (-1.65%) 16:34 04/20/18 04/20 16:34 04/20/18 16:34 Syndicate	Breaking Syndicate news story on Whirlpool » Whirlpool files automatic… Whirlpool files automatic mixed securities shelf 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	24 Apr

Events

Earnings calls, analyst events, roadshows and more

Tomorrow at 00:00

2018 Spring Meeting Conferences

Washington, D.C.
Tomorrow at 00:00

28th European Congress of Clinical Microbiology & Infectious Diseases: ECCMID Conferences

Feria de Madrid, Madrid
LEVB
Tomorrow at 12:30

Level Brands - LEVB Conference Calls
2018-04-23 at 00:00

28th European Congress of Clinical Microbiology & Infectious Diseases: ECCMID Conferences

Feria de Madrid, Madrid
NVS ...
2018-04-23 at 00:00

Biostatistics Industry & Regulator Forum Conferences

Bethesda North Marriott Hotel, North Bethesda, MD
2018-04-23 at 00:00

CinemaCon Conferences

Caesars Palace, Las Vegas, NV
AMC ...
2018-04-23 at 00:00

RBC Hosted Company Meetings at CinemaCon Show Conferences

Las Vegas, NV
2018-04-23 at 00:00

2018 New York Sohn Investment Conference Conferences

David Geffen Hall at Lincoln Center, New York, NY
CRAY
2018-04-23 at 00:00

Cray Firm Sponsored Meetings

Los Angeles, CA
OMAB
2018-04-23 at 00:00

OMA Airports Firm Sponsored Meetings

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	CLVS X CLVS Clovis Secondary Managers: JPMorgan & BofA/Merrill Priced at: $54.41 1.838M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TMQ X TMQ Trilogy Metals Spot Secondary Managers: Cantor Fitzgerald Priced at: $1.16 21.552M Shares
Tues	BLCM X BLCM Bellicum Pharmaceuticals Secondary Managers: Citi & Jefferies Priced at: $7.50 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MBII X MBII Marrone Bio Spot Secondary Managers: National Securities Priced at: $1.65 7.275M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	EAF X EAF GrafTech IPO Managers: JPMorgan, Credit Suisse, Citi, RBC Capital & HSBC, BMO Capital, BNP Paribas, CIBC, National Bank, TD Securities Priced at: $15.00 35M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MOR X MOR MorphoSys IPO Managers: Goldman Sachs, JPMorgan & Leerink, Berenberg Capital, JMP Securities Priced at: $25.04 8.3M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SURF X SURF Surface Oncology IPO Managers: Goldman Sachs, Cowen & Evercore ISI Priced at: $15.00 7.2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AGLE X AGLE Aeglea BioTherapeutics Secondary Managers: Evercore ISI & BMO Capital, Jones Trading Priced at: $8.00 4.5M Shares APLS X APLS Apellis Secondary Managers: Citi, JPMorgan & Cowen Priced at: $25.50 5.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CART X CART Carolina Trust BancShares Secondary Managers: Sandler ONeill Priced at: $8.00 2.31M Shares SJI X SJI South Jersey Industries Secondary Managers: BofA/Merrill, Guggenheim & Wells Fargo, JPMorgan, Morgan Stanley, PNC Capital, TD Securities Priced at: $29.50 11.017M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ASPU X ASPU Aspen Group Spot Secondary Managers: Roth Capital Priced at: $7.15 2.8M Shares HMNY X HMNY Helios and Matheson Spot Secondary Managers: Canaccord Priced at: $2.75 10.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TRCH X TRCH Torchlight Energy Resources Spot Secondary Managers: Roth Capital Priced at: $1.15 5M Shares
Thurs	LEVL X LEVL Level One IPO Managers: Raymond James & Keefe Bruyette, Piper Jaffray Priced at: $28.00 1.2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PVTL X PVTL Pivotal Software IPO Managers: Morgan Stanley, Goldman Sachs & Citi, BofA/Merrill, Barclays, Credit Suisse, RBC Capital, UBS, Wells Fargo, KeyBanc, William Blair, Mischler, Ramirez, Siebert Cisneros, Williams Capital Priced at: $15.00 37M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RIGL X RIGL Rigel Pharmaceuticals Secondary Managers: Jefferies, Piper Jaffray & BMO Capital, H.C. Wainwright Priced at: $3.90 16M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	No deals
Wed	VRIO X VRIO Vrio IPO Managers: Goldman Sachs, JPMorgan, Citi & Morgan Stanley, BofA/Merrill, Barclays, BTG Pactual, Credit Suisse, Deutsche Bank, Itau BBA, Santander, BBSI, PARI, BBBI $16.00-17.00 29.684M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	FCI X FCI FirstCaribbean IPO Managers: Barclays, UBS & CIBC, Keefe Bruyette, Raymond James, Sandler ONeill, Wells Fargo $22.00-25.00 9.6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

View All Syndicate Announcements »

Arena Pharmaceuticals to present Phase 2 ralinepag results at ISHLT

TODAY'S FREE FLY STORIES

Get Full Fly Access